|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent GLSI insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why GLSI insider buys are important for investors to follow.
Date | Insider | Price | Amount |
4-1-2024 Insider Buy |
Snehal Patel CEO and CFO |
$19.08
CAGR »
|
$57,240.00 3,000 shares |
3-22-2024 Insider Buy |
Snehal Patel CEO and CFO |
$19.98
CAGR »
|
$49,950.00 2,500 shares |
3-20-2024 Insider Buy |
Snehal Patel CEO and CFO |
$17.68
CAGR »
|
$26,520.00 1,500 shares |
3-5-2024 Insider Buy |
Snehal Patel CEO and CFO |
$12.49
CAGR »
|
$43,715.00 3,500 shares |
3-4-2024 Insider Buy |
Snehal Patel CEO and CFO |
$13.03
CAGR »
|
$53,423.00 4,100 shares |
2-16-2024 Insider Buy |
Snehal Patel CEO and CFO |
$11.16
CAGR »
|
$120,528.00 10,800 shares |
11-3-2023 Insider Buy |
Snehal Patel CEO and CFO |
$9.11
CAGR »
|
$31,885.00 3,500 shares |
10-27-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$8.57
CAGR »
|
$4,285.00 500 shares |
10-26-2023 Insider Buy |
Snehal Patel CEO and CFO |
$7.97
CAGR »
|
$19,925.00 2,500 shares |
10-25-2023 Insider Buy |
Snehal Patel CEO and CFO |
$7.91
CAGR »
|
$19,775.00 2,500 shares |
10-10-2023 Insider Buy |
Snehal Patel CEO and CFO |
$9.07
CAGR »
|
$9,070.00 1,000 shares |
10-4-2023 Insider Buy |
Snehal Patel CEO and CFO |
$8.63
CAGR »
|
$17,260.00 2,000 shares |
9-26-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$8.71
CAGR »
|
$5,226.00 600 shares |
9-19-2023 Insider Buy |
Snehal Patel CEO and CFO |
$8.95
CAGR »
|
$35,800.00 4,000 shares |
9-11-2023 Insider Buy |
Snehal Patel CEO and CFO |
$9.48
CAGR »
|
$9,480.00 1,000 shares |
8-22-2023 Insider Buy |
Snehal Patel CEO and CFO |
$9.97
CAGR »
|
$9,970.00 1,000 shares |
8-4-2023 Insider Buy |
Snehal Patel CEO and CFO |
$10.55
CAGR »
|
$21,100.00 2,000 shares |
7-21-2023 Insider Buy |
Snehal Patel CEO and CFO |
$9.20
CAGR »
|
$9,200.00 1,000 shares |
7-13-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$9.49
CAGR »
|
$2,372.50 250 shares |
5-17-2023 Insider Buy |
Snehal Patel CEO and CFO |
$11.69
CAGR »
|
$11,690.00 1,000 shares |
4-28-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$11.22
CAGR »
|
$2,805.00 250 shares |
4-19-2023 Insider Buy |
Snehal Patel CEO and CFO |
$11.10
CAGR »
|
$77,700.00 7,000 shares |
4-18-2023 Insider Buy |
Snehal Patel CEO and CFO |
$11.12
CAGR »
|
$22,240.00 2,000 shares |
4-11-2023 Insider Buy |
Snehal Patel CEO and CFO |
$12.42
CAGR »
|
$62,100.00 5,000 shares |
4-11-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$11.87
CAGR »
|
$11,870.00 1,000 shares |
3-15-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$12.71
CAGR »
|
$3,177.50 250 shares |
3-10-2023 Insider Buy |
Snehal Patel CEO and CFO |
$12.12
CAGR »
|
$12,120.00 1,000 shares |
2-24-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$15.39
CAGR »
|
$3,848.75 250 shares |
2-17-2023 Insider Buy |
Snehal Patel CEO and CFO |
$16.53
CAGR »
|
$9,918.00 600 shares |
2-10-2023 Insider Buy |
Snehal Patel CEO and CFO |
$18.68
CAGR »
|
$18,680.00 1,000 shares |
2-3-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$20.84
CAGR »
|
$5,210.00 250 shares |
1-27-2023 Insider Buy |
Snehal Patel CEO and CFO |
$19.35
CAGR »
|
$38,700.00 2,000 shares |
1-27-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$19.20
CAGR »
|
$4,800.00 250 shares |
1-20-2023 Insider Buy |
Snehal Patel CEO and CFO |
$17.37
CAGR »
|
$26,055.00 1,500 shares |
1-13-2023 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$16.50
CAGR »
|
$4,125.00 250 shares |
1-6-2023 Insider Buy |
Snehal Patel CEO and CFO |
$15.18
CAGR »
|
$22,770.00 1,500 shares |
12-29-2022 Insider Buy |
Snehal Patel CEO and CFO |
$15.19
CAGR »
|
$60,760.00 4,000 shares |
12-16-2022 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$12.94
CAGR »
|
$3,235.00 250 shares |
12-16-2022 Insider Buy |
Snehal Patel CEO and CFO |
$13.01
CAGR »
|
$13,010.00 1,000 shares |
12-9-2022 Insider Buy |
Snehal Patel CEO and CFO |
$13.11
CAGR »
|
$26,220.00 2,000 shares |
12-2-2022 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$13.98
CAGR »
|
$3,495.00 250 shares |
12-2-2022 Insider Buy |
Snehal Patel CEO and CFO |
$13.84
CAGR »
|
$13,840.00 1,000 shares |
11-2-2022 Insider Buy |
Snehal Patel CEO and CFO |
$8.79
CAGR »
|
$17,580.00 2,000 shares |
10-14-2022 Insider Buy |
Snehal Patel CEO and CFO |
$9.75
CAGR »
|
$29,250.00 3,000 shares |
10-7-2022 Insider Buy |
Snehal Patel CEO and CFO |
$9.72
CAGR »
|
$19,440.00 2,000 shares |
9-30-2022 Insider Buy |
Snehal Patel CEO and CFO |
$9.46
CAGR »
|
$9,460.00 1,000 shares |
9-29-2022 Insider Buy |
Snehal Patel CEO and CFO |
$9.23
CAGR »
|
$9,230.00 1,000 shares |
6-24-2022 Insider Buy |
Snehal Patel CEO and CFO |
$9.13
CAGR »
|
$264,770.00 29,000 shares |
6-16-2022 Insider Buy |
Snehal Patel CEO and CFO |
$7.13
CAGR »
|
$57,040.00 8,000 shares |
6-14-2022 Insider Buy |
Snehal Patel CEO and CFO |
$7.91
CAGR »
|
$94,920.00 12,000 shares |
6-10-2022 Insider Buy |
Snehal Patel CEO and CFO |
$8.33
CAGR »
|
$99,960.00 12,000 shares |
6-9-2022 Insider Buy |
Snehal Patel CEO and CFO |
$10.90
CAGR »
|
$49,050.00 4,500 shares |
6-7-2022 Insider Buy |
Snehal Patel CEO and CFO |
$8.55
CAGR »
|
$51,300.00 6,000 shares |
6-3-2022 Insider Buy |
Snehal Patel CEO and CFO |
$8.35
CAGR »
|
$77,237.50 9,250 shares |
6-2-2022 Insider Buy |
Snehal Patel CEO and CFO |
$7.38
CAGR »
|
$49,992.12 6,774 shares |
4-25-2022 Insider Buy |
Frank Joseph Daugherty Chief Medical Officer |
$16.25
CAGR »
|
$16,250.00 1,000 shares |
4-21-2022 Insider Buy |
Snehal Patel CEO and CFO |
$16.09
CAGR »
|
$96,540.00 6,000 shares |
4-19-2022 Insider Buy |
Snehal Patel CEO and CFO |
$16.74
CAGR »
|
$100,440.00 6,000 shares |
4-19-2022 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$16.74
CAGR »
|
$8,370.00 500 shares |
2-11-2022 Insider Buy |
Snehal Patel CEO and CFO |
$19.80
CAGR »
|
$108,900.00 5,500 shares |
2-4-2022 Insider Buy |
Snehal Patel CEO and CFO |
$19.59
CAGR »
|
$97,950.00 5,000 shares |
1-31-2022 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$18.47
CAGR »
|
$9,235.00 500 shares |
1-21-2022 Insider Buy |
Kenneth Hallock Director |
$16.32
CAGR »
|
$4,896.00 300 shares |
1-21-2022 Insider Buy |
Jaye Thompson VP Clinical Reg Affairs |
$16.33
CAGR »
|
$8,165.00 500 shares |
1-18-2022 Insider Buy |
Jaye Thompson VP Clinical Reg. Affairs |
$18.87
CAGR »
|
$9,435.00 500 shares |
1-13-2022 Insider Buy |
Snehal Patel CEO and CFO |
$19.99
CAGR »
|
$19,990.00 1,000 shares |
1-13-2022 Insider Buy |
Frank Joseph Daugherty Chief Medical Officer |
$19.99
CAGR »
|
$19,990.00 1,000 shares |
1-13-2022 Insider Buy |
Jaye Thompson VP Clinical Reg. Affairs |
$19.99
CAGR »
|
$19,990.00 1,000 shares |
1-3-2022 Insider Buy |
Snehal Patel CEO and CFO |
$23.82
CAGR »
|
$48,830.79 2,050 shares |
12-14-2021 Insider Buy |
David McWilliams Director |
$27.56
CAGR »
|
$5,512.18 200 shares |
12-14-2021 Insider Buy |
Frank Joseph Daugherty Chief Medical Officer |
$26.99
CAGR »
|
$29,983.45 1,111 shares |
12-14-2021 Insider Buy |
Snehal Patel CEO and CFO |
$27.17
CAGR »
|
$49,992.43 1,840 shares |
4-13-2021 Insider Buy |
Snehal Patel CEO and CFO |
$36.98
CAGR »
|
$99,852.75 2,700 shares |
11-24-2020 Insider Buy |
Kenneth Hallock Director |
$5.39
CAGR »
|
$5,386.00 1,000 shares |
11-23-2020 Insider Buy |
Frank Joseph Daugherty Chief Medical Officer |
$5.10
CAGR »
|
$5,100.00 1,000 shares |
11-20-2020 Insider Buy |
Eric Rothe Director |
$5.40
CAGR »
|
$10,800.00 2,000 shares |
11-20-2020 Insider Buy |
Kenneth Hallock Director |
$5.37
CAGR »
|
$5,370.00 1,000 shares |
11-20-2020 Insider Buy |
David McWilliams Director |
$5.40
CAGR »
|
$8,100.00 1,500 shares |
11-19-2020 Insider Buy |
Snehal Patel CEO and CFO |
$5.40
CAGR »
|
$10,795.40 2,000 shares |
9-29-2020 Insider Buy |
Kenneth Hallock Director |
$4.60
CAGR »
|
$38,352.63 8,333 shares |
9-29-2020 Insider Buy |
Snehal Patel CEO and CFO |
$4.60
CAGR »
|
$76,709.87 16,667 shares |
9-29-2020 Insider Buy |
David McWilliams Director |
$5.75
CAGR »
|
$14,996.00 2,608 shares |
9-29-2020 Insider Buy |
Frank Joseph Daugherty Chief Medical Officer |
$5.75
CAGR »
|
$9,999.25 1,739 shares |
9-29-2020 Insider Buy |
Snehal Patel CEO and CFO |
$5.75
CAGR »
|
$657,495.25 114,347 shares |
9-29-2020 Insider Buy |
Kenneth Hallock Director |
$5.75
CAGR »
|
$429,996.50 74,782 shares |
Also See: Institutional Holders of GLSI
Also See: SEC filings
Below we present the annualized performance delivered by GLSI stock since 4-1-2024 (the date of the most recent
insider purchase). The performance of the investment from the time GLSI insider buying occurred is the ultimate
test of whether insiders were right about GLSI being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/02/2024 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$17.49 |
|
End price/share: |
$12.89 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-26.30% |
|
Annualized Gain: |
-599.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,370.00 |
|
Years: |
0.04 |
|
GLSI Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent GLSI insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding GLSI
|
|